Sidley Represents Sensei Biotherapeutics in Acquisition of Faeth Therapeutics

Sidley represented Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, in its acquisition of Faeth Therapeutics Inc., a clinical-stage biotechnology company developing multi-node therapies targeting tumor metabolism and signaling.

Concurrent with the acquisition, Sidley also represented Sensei in its definitive agreement for the sale of Series B non-voting convertible preferred stock in a private placement expected to result in gross proceeds of approximately US$200 million.

The Sidley team was led by Asher Rubin (Technology and Life Sciences Transactions), John Butler (M&A), Istvan Hajdu (Capital Markets), and Nikita Ponomarev (M&A), and included Michael Rohr, Emily Chazen, Xi Zhao, and law clerk Christine Seo (M&A); Nick DeAngelis, Sonia Gupta Barros, Kendell Lee, and Eric Carlson (Capital Markets); Adriana Tibbitts, Collin Marshall, and Kayla Nguyen (Technology and Life Sciences Transactions); Gregory Marrs, Christian Pilhofer, Ryan McLeod, and Madeline Clasen (Employee Benefits and Executive Compensation); Christian Brause and Tyler Combest (Tax); Eric Hoffman (Labor, Employment and Immigration); and IP Transactions Specialist Raza Siddiqui.